Pursuant to provision of Regulations 30 and 34 of the SEBI LODR Regulations, 2015, we wish to inform that the 49th Annual General Meeting of the Company will be held on Tuesday, 22nd day ....

Date: 24th August, 2026 Corporate Services Department, BSE Limited, Phiroze Jeejeebhoy Towers, 1st Floor, Dalal Street, Fort, Mumbai - 400001. Scrip Code: 540204 Sub: 49th Annual Report for the Financial Year 2025-26 Dear Sir/ Madam, Pursuant to provision of Regulations 30 and 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the 49th Annual General Meeting of the Company will be held on Tuesday, 22nd day of September, 2026 at 04:00 P.M. (IST) through Video Conferencing/ Other Audio Visual Means (“VC/ OAVM”). Please find enclosed the copy of the Annual Report of 49th AGM for the Financial Year 2025-26 of the Company. The 49th Annual Report is also being uploaded on the website of the Company at www.eikolifesciences.com. In compliance with the SEBI circulars, the Annual Report along with the Notice of the AGM is being sent only by electronic mode to those shareholders whose e-mail addresses are registered with the Company/ Registrar and Transfer Agent of the Company/Depository Participants. For those shareholders who have not registered their email ids, a letter providing a weblink from where the Notice of the AGM and Annual Report for the financial year 2025-26 can be accessed is being sent. You are requested to kindly take the afore-mentioned on record and oblige. Thanking you, For Eiko Lifesciences Limited Chintan Doshi Company Secretary and Compliance Officer Membership No: A36190 Eiko LifeSciences Limited, CIN: L65993MH1977PLC258134 Registered Address: 604, Centrum, Opp. TMC Office, Near Satkar Grande Hotel, Wagle Estate, Thane MH 400604 Mobile No.: +919082668855; Email id: investor.rela(cid:415)ons@eikolifesciences.com website: www.eikolifesciences.com Speciality Chemicals & API Logistics & Container Leasing R&D and Scientific Solutions 4 9 T H A N N U A L R E P O R T F Y 2 0 2 5 - 2 6 B O A R D O F D I R E C T O R S & K M P Mr. Laxmikant Ramprasad Kabra Chairperson & Non-Executive Director Mr. Bhavesh Dhirajlal Tanna Non-Executive Director Mr. Sumukh Vartak Whole-Time Director Mr. Rajkumar Govindas Baheti Independent Director Ms. Kajal Dhanpatraj Kothari Independent Director Ms. Hasti Doshi Independent Director (Resigned w.e.f. 24/08/2026) Mr. Suraj Mahadev Gaikwad Additional Independent Director (Appointed w.e.f. 24/08/2026) Mr. Jaid Ismail Kojar Chief Financial Officer Mr. Chintan Doshi Company Secretary & Compliance Officer C O R P O R A T E I N F O R M A T I O N SECRETARIAL AUDITORS STATUTORY AUDITORS M/s Shravan A. Gupta and Associates M/s P S V Jain and Associates Company Secretaries Chartered Accountants INTERNAL AUDITORS REGISTERED OFFICE M/s. NP Rajput & Co Unit No. 604, 6th Floor, Centrum IT Park, S G Barve Road, Near Chartered Accountants Mulund Check Naka, Wagle Estate, Thane West 400 604 BANKER: CIN: Bank of India (BOI) L65993MH1977PLC258134 REGISTRARS AND SHARE TRANSFER AGENT Bigshare Services Private Limited Off No S6-2, 6th Floor, Pinnacle Business Park, Mahakali Caves Road, Andheri East, Mumbai 400093 Phone: +91 22 62638200 E-mail: info@bigshareonline.com Website: www.bigshareonline.com 49TH ANNUAL GEENRAL MEETING Date: 22nd September 2026 Day: Tuesday Time: 04:00 PM Mode: Video Conferencing Page | 1 I N S I D E T H E R E P O R T From the Chairperson’s desk 3 Notice of Annual General Meeting 4 Board’s Report 1 4 Secretarial Audit Report 2 6 Secretarial Audit Report of Material Unlisted Subsidiary 2 9 Corporate Governance Report 3 4 Compliance Certificate from CFO & WTD 4 7 Declaration regarding compliance with Business Code of Conduct 4 7 Certificate on Non-Disqualification of Directors 4 8 Independent Auditor’s Certificate on Corporate Governance 4 9 Management Discussion and Analysis 5 0 Standalone Independent Auditor’s Report 5 5 Standalone Balance Sheet 6 3 Standalone Statement of Profit and Loss 6 4 Standalone Statement of Cash Flows 6 5 Standalone Statement of Changes in Equity 6 6 Standalone Notes to the Financial Statement 6 7 Consolidated Independent Auditor’s Report 8 5 Consolidated Balance Sheet 9 1 Consolidated Statement of Profit and Loss 9 2 Consolidated Statement of Cash Flows 9 3 Consolidated Statement of Changes in Equity 9 4 Consolidated Notes to the Financial Statement 9 5 Page | 2 FROM THE CHAIRPERSON’S DESK Dear Shareholders, FY 2025-26 was, in many ways, the most transformative year in our Company's recent history. We delivered strong growth despite a challenging global environment marked by geopolitical uncertainties, volatile input costs and uneven demand across international markets. During the year, our focus remained firmly on strengthening the core business while making deliberate investments in the platforms that will shape our next phase of growth. On a consolidated basis, the Company recorded revenue from operations of ₹5,257.14 lakhs during FY 2025-26. Profit after tax increased to ₹358.11 lakhs, compared with ₹174.08 lakhs in the previous year, representing growth of more than 100%. Our EBITDA margin improved to 11.19%, reflecting better operating leverage, improved cost discipline and the continued strengthening of our business portfolio. These results are particularly encouraging because they were achieved alongside investments in new businesses and capabilities that are expected to contribute more meaningfully over the coming years. A Strategic Step into Pharmaceutical Formulations The most significant development during the year was our strategic acquisition of a 51% stake in SSM Formulations Private Limited, for an aggregate consideration of approximately ₹18.15 crore. This acquisition represents an important step in our evolution from a specialty chemicals company towards a more integrated chemical and pharmaceutical enterprise. Our entry into pharmaceutical formulations complements our existing capabilities in specialty chemicals and pharma-related products and provides us with an opportunity to participate across a broader part of the pharmaceutical value chain. We believe this platform can create meaningful opportunities for growth, diversification and operational synergies over the long term. Strengthening Our Capital Base We also took important steps to strengthen our financial capacity to support this growth. During the year, the Company approved and allotted 29,50,000 warrants convertible into equity and 6,25,000 equity shares on a preferential basis to investors belonging to the Promoter/Promoter Group and Non-Promoter/Public categories. The participation of both our existing promoters and new investors is an important endorsement of the Company's strategy and future potential. The capital raised provides us with greater financial flexibility to pursue acquisition-led and organic growth opportunities. We have also enhanced our working capital facilities with Bank of India, supporting our ability to scale operations as opportunities arise. Building the Organization for the Next Phase Growth at the scale we envisage requires not only capital and opportunities, but also the right leadership. During the year, we strengthened our leadership team with the appointment of Mr. Sumukh Vartak as Whole-Time Director. His appointment reflects our commitment to building a management team capable of executing an increasingly diverse and complex business strategy spanning specialty chemicals, logistics, research and development, and pharmaceutical formulations. Our logistics subsidiary, EikoVivify Logistics Private Limited, continued to build its container leasing business during the year, while Eiko Scientific Solutions LLP remained focused on research and development in specialty chemicals and healthcare. These businesses form important components of our broader strategy to create a diversified and integrated enterprise with multiple avenues for future growth. Looking Ahead The opportunities before us are significant, but we remain conscious of the challenges. Global chemical markets continue to experience competitive pressures, exce [Showing first 8,000 characters — download PDF for full document]